Windtree Therapeutics Inc
WINT0.110USD
0.000
Close 12/11, 16:00（ET）Quotes delayed by 15 min
1.02MMarket Cap
LossP/E TTM
More Details of Windtree Therapeutics Inc Company
Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Its lead product candidate, istaroxime, is a dual-acting agent being developed to increase blood pressure and improve cardiac function in patients with cardiogenic shock and to improve cardiac function in patients with acute heart failure (AHF) and reverse the hypotension and hypoperfusion associated with heart failure that deteriorates to cardiogenic shock. The Company also has a licensing business model with partnership out-licenses in place.
Windtree Therapeutics Inc Info
Ticker SymbolWINT
Company nameWindtree Therapeutics Inc
IPO dateAug 09, 1995
CEOMr. Jed Latkin
Number of employees14
Security typeOrdinary Share
Fiscal year-endAug 09
Address2600 Kelly Rd Ste 100
CityWARRINGTON
Stock exchangeUS 'Other OTC' and Grey Market
CountryUnited States of America
Postal code18976-3652
Phone12154889300
Websitehttps://windtreetx.com/
Ticker SymbolWINT
IPO dateAug 09, 1995
CEOMr. Jed Latkin
Company Executives of Windtree Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Strobeck, Ph.D.
Dr. Mark Strobeck, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.00
--
Dr. Randall White, Ph.D.
Dr. Randall White, Ph.D.
Vice President - Clinical Program Management
Vice President - Clinical Program Management
--
--
Mr. Jed Latkin
Mr. Jed Latkin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Saundra Pelletier
Ms. Saundra Pelletier
Independent Director
Independent Director
--
--
Mr. Eric L. Curtis
Mr. Eric L. Curtis
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. Andrew Albert Kucharchuk
Mr. Andrew Albert Kucharchuk
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Strobeck, Ph.D.
Dr. Mark Strobeck, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.00
--
Dr. Randall White, Ph.D.
Dr. Randall White, Ph.D.
Vice President - Clinical Program Management
Vice President - Clinical Program Management
--
--
Mr. Jed Latkin
Mr. Jed Latkin
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Saundra Pelletier
Ms. Saundra Pelletier
Independent Director
Independent Director
--
--
Mr. Eric L. Curtis
Mr. Eric L. Curtis
Chief Operating Officer, Senior Vice President
Chief Operating Officer, Senior Vice President
--
--
Mr. Andrew Albert Kucharchuk
Mr. Andrew Albert Kucharchuk
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
24
16.97K
0.06%
-88.88K
2025Q2
34
46.40K
1.22%
+34.94K
2025Q1
34
45.70K
1.25%
+34.98K
2024Q4
45
7.13K
0.35%
+2.06K
2024Q3
40
4.08K
10.41%
+2.25K
2024Q2
40
845.00
3.85%
-949.00
2024Q1
42
1.57K
11.07%
-358.00
2023Q4
44
1.21K
12.04%
+82.00
2023Q3
46
1.23K
32.70%
+448.00
2023Q2
46
1.02K
29.34%
+410.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Blackstone Alternative Investment Advisors LLC
38.00
0%
--
--
Jun 30, 2025
Alyeska Investment Group, L.P.
--
0%
-152.00
-100.00%
Mar 31, 2024
Curtis (Eric)
1.00
0%
--
--
Jul 23, 2025
Geode Capital Management, L.L.C.
--
0%
-1.18K
-100.00%
Mar 31, 2025
Jane Street Capital, L.L.C.
14.60K
0.05%
+14.60K
--
Jun 30, 2025
Aperio Group, LLC
--
0%
--
--
Dec 31, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 18, 2025
Merger
50→1
Feb 18, 2025
Merger
50→1
Feb 18, 2025
Merger
50→1
Feb 18, 2025
Merger
50→1
Apr 18, 2024
Merger
18→1
Apr 18, 2024
Merger
18→1
Date
Type
Ratio
Feb 18, 2025
Merger
50→1
Feb 18, 2025
Merger
50→1
Feb 18, 2025
Merger
50→1
Feb 18, 2025
Merger
50→1
Apr 18, 2024
Merger
18→1
Apr 18, 2024
Merger
18→1
Apr 18, 2024
Merger
18→1
Apr 18, 2024
Merger
18→1
Feb 23, 2023
Merger
50→1
Feb 23, 2023
Merger
50→1
View more
FAQs
Who are the top five shareholders of Windtree Therapeutics Inc?
The top five shareholders of Windtree Therapeutics Inc are:
Blackstone Alternative Investment Advisors LLC holds 38.00 shares, accounting for 0.00% of the total shares.
Alyeska Investment Group, L.P. holds 0.00 shares, accounting for 0.00% of the total shares.
Curtis (Eric) holds 1.00 shares, accounting for 0.00% of the total shares.
Geode Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
Jane Street Capital, L.L.C. holds 14.60K shares, accounting for 0.05% of the total shares.
Blackstone Alternative Investment Advisors LLC holds 38.00 shares, accounting for 0.00% of the total shares.
Alyeska Investment Group, L.P. holds 0.00 shares, accounting for 0.00% of the total shares.
Curtis (Eric) holds 1.00 shares, accounting for 0.00% of the total shares.
Geode Capital Management, L.L.C. holds 0.00 shares, accounting for 0.00% of the total shares.
Jane Street Capital, L.L.C. holds 14.60K shares, accounting for 0.05% of the total shares.
What are the top three shareholder types of Windtree Therapeutics Inc?
The top three shareholder types of Windtree Therapeutics Inc are:
Other
Other
How many institutions hold shares of Windtree Therapeutics Inc (WINT)?
As of 2025Q3, 24 institutions hold shares of Windtree Therapeutics Inc, with a combined market value of approximately 16.97K, accounting for 0.06% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.16%.
What is the biggest source of revenue for Windtree Therapeutics Inc?
In --, the -- business generated the highest revenue for Windtree Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
